SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer

Libang Yang

doi:10.3390/ijms241512500

SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer

Libang Yang

Pulmonary, Allergy, Critical Care and Sleep Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Cancer markers are measurable molecules in the blood or tissue that are produced by tumor cells or immune cells in response to cancer progression. They play an important role in clinical diagnosis, prognosis, and anti-drug monitoring. Although DNA, RNA, and even physical images have been used, proteins continue to be the most common marker. There are currently no specific markers for lung cancer. Metastatic lung cancer, particularly non-small-cell lung cancer (NSCLC), is one of the most common causes of death. SFPQ, YY1, RTN4, RICTOR, LARP6, and HELLS are expressed at higher levels in cells from NSCLC than in control or cells from inflammatory diseases. SFPQ shows the most difference between the three cell types. Furthermore, the cytoplasmic isoform of SFPQ is only found in advanced cancers. We have developed ELISAs to detect SFPQ and the long and short isoforms. Evidence has shown that the short isoform exists primarily in cancers. Furthermore, immunocytometry studies and IHC analysis have revealed that SFPQ levels are consistent with ELISA results. In addition, enhanced DNA methylation in the SFPQ gene may facilitate the SFPQ expression differences between control and cancer cells. Considering this, elevated SFPQ level and the isoform location could serve as a cancer diagnostic and prognostic marker.

Original language	English (US)
Article number	12500
Journal	International Journal of Molecular Sciences
Volume	24
Issue number	15
DOIs	https://doi.org/10.3390/ijms241512500
State	Published - Aug 2023

Bibliographical note

Funding Information:
Human sample collection and screening were conducted by Bionet at the University of Minnesota. The gene molecular work was performed at the viral vector and cloning Core at the University of Minnesota; supporting agencies are listed here: https://vvcc.umn.edu/ , accessed on 1 June 2023. Sample collection was supported by the National Institutes of Health’s National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health’s National Center for Advancing Translational Sciences.

Funding Information:
This work was supported by National Institutes of Health grants R01 HL125227 to C.A.H. and UL1TR002494 to J.P. The authors have no conflicting financial interests.

Publisher Copyright:
© 2023 by the authors.

PubMed: MeSH publication types

Journal Article

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.3390/ijms241512500

Find It

Find It at U of M Libraries

Cite this

@article{801774557ba04d50bf9124932b80de59,

title = "SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer",

abstract = "Cancer markers are measurable molecules in the blood or tissue that are produced by tumor cells or immune cells in response to cancer progression. They play an important role in clinical diagnosis, prognosis, and anti-drug monitoring. Although DNA, RNA, and even physical images have been used, proteins continue to be the most common marker. There are currently no specific markers for lung cancer. Metastatic lung cancer, particularly non-small-cell lung cancer (NSCLC), is one of the most common causes of death. SFPQ, YY1, RTN4, RICTOR, LARP6, and HELLS are expressed at higher levels in cells from NSCLC than in control or cells from inflammatory diseases. SFPQ shows the most difference between the three cell types. Furthermore, the cytoplasmic isoform of SFPQ is only found in advanced cancers. We have developed ELISAs to detect SFPQ and the long and short isoforms. Evidence has shown that the short isoform exists primarily in cancers. Furthermore, immunocytometry studies and IHC analysis have revealed that SFPQ levels are consistent with ELISA results. In addition, enhanced DNA methylation in the SFPQ gene may facilitate the SFPQ expression differences between control and cancer cells. Considering this, elevated SFPQ level and the isoform location could serve as a cancer diagnostic and prognostic marker.",

author = "Libang Yang",

note = "Funding Information: Human sample collection and screening were conducted by Bionet at the University of Minnesota. The gene molecular work was performed at the viral vector and cloning Core at the University of Minnesota; supporting agencies are listed here: https://vvcc.umn.edu/ , accessed on 1 June 2023. Sample collection was supported by the National Institutes of Health{\textquoteright}s National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health{\textquoteright}s National Center for Advancing Translational Sciences. Funding Information: This work was supported by National Institutes of Health grants R01 HL125227 to C.A.H. and UL1TR002494 to J.P. The authors have no conflicting financial interests. Publisher Copyright: {\textcopyright} 2023 by the authors.",

year = "2023",

month = aug,

doi = "10.3390/ijms241512500",

language = "English (US)",

volume = "24",

journal = "International Journal of Molecular Sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "15",

}

TY - JOUR

T1 - SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer

AU - Yang, Libang

N1 - Funding Information: Human sample collection and screening were conducted by Bionet at the University of Minnesota. The gene molecular work was performed at the viral vector and cloning Core at the University of Minnesota; supporting agencies are listed here: https://vvcc.umn.edu/ , accessed on 1 June 2023. Sample collection was supported by the National Institutes of Health’s National Center for Advancing Translational Sciences, grant UL1TR002494. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health’s National Center for Advancing Translational Sciences. Funding Information: This work was supported by National Institutes of Health grants R01 HL125227 to C.A.H. and UL1TR002494 to J.P. The authors have no conflicting financial interests. Publisher Copyright: © 2023 by the authors.

PY - 2023/8

Y1 - 2023/8

N2 - Cancer markers are measurable molecules in the blood or tissue that are produced by tumor cells or immune cells in response to cancer progression. They play an important role in clinical diagnosis, prognosis, and anti-drug monitoring. Although DNA, RNA, and even physical images have been used, proteins continue to be the most common marker. There are currently no specific markers for lung cancer. Metastatic lung cancer, particularly non-small-cell lung cancer (NSCLC), is one of the most common causes of death. SFPQ, YY1, RTN4, RICTOR, LARP6, and HELLS are expressed at higher levels in cells from NSCLC than in control or cells from inflammatory diseases. SFPQ shows the most difference between the three cell types. Furthermore, the cytoplasmic isoform of SFPQ is only found in advanced cancers. We have developed ELISAs to detect SFPQ and the long and short isoforms. Evidence has shown that the short isoform exists primarily in cancers. Furthermore, immunocytometry studies and IHC analysis have revealed that SFPQ levels are consistent with ELISA results. In addition, enhanced DNA methylation in the SFPQ gene may facilitate the SFPQ expression differences between control and cancer cells. Considering this, elevated SFPQ level and the isoform location could serve as a cancer diagnostic and prognostic marker.

AB - Cancer markers are measurable molecules in the blood or tissue that are produced by tumor cells or immune cells in response to cancer progression. They play an important role in clinical diagnosis, prognosis, and anti-drug monitoring. Although DNA, RNA, and even physical images have been used, proteins continue to be the most common marker. There are currently no specific markers for lung cancer. Metastatic lung cancer, particularly non-small-cell lung cancer (NSCLC), is one of the most common causes of death. SFPQ, YY1, RTN4, RICTOR, LARP6, and HELLS are expressed at higher levels in cells from NSCLC than in control or cells from inflammatory diseases. SFPQ shows the most difference between the three cell types. Furthermore, the cytoplasmic isoform of SFPQ is only found in advanced cancers. We have developed ELISAs to detect SFPQ and the long and short isoforms. Evidence has shown that the short isoform exists primarily in cancers. Furthermore, immunocytometry studies and IHC analysis have revealed that SFPQ levels are consistent with ELISA results. In addition, enhanced DNA methylation in the SFPQ gene may facilitate the SFPQ expression differences between control and cancer cells. Considering this, elevated SFPQ level and the isoform location could serve as a cancer diagnostic and prognostic marker.

U2 - 10.3390/ijms241512500

DO - 10.3390/ijms241512500

M3 - Article

C2 - 37569873

SN - 1661-6596

VL - 24

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

IS - 15

M1 - 12500

ER -

SFPQ and Its Isoform as Potential Biomarker for Non-Small-Cell Lung Cancer

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Fingerprint

Cite this